Tong Qiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tong Qiu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Jiangyuan Zhou
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
5 shared publications - Kaiying Yang
Department of Pediatric Surgery, Guangzhou Women and Children's Medical Center, National Children's Medical Center for South Central Region, Guangzhou Medical University, Guangzhou, China
4 shared publications - Xue Gong
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
4 shared publications - Yi Ji
Division of Oncology, Department of Pediatric Surgery West China Hospital of Sichuan University Chengdu China
4 shared publications - Xuepeng Zhang
Pediatric Intensive Care Unit, Department of Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, China
3 shared publications - Yuru Lan
Division of Oncology, Department of Pediatric Surgery, West China Hospital of Sichuan University, Chengdu, China
3 shared publications
Latest Publications
- 19 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1706-1710.e9
PPARγ promotes kaposiform hemangioendothelioma progression via the CD36-mediated lipid metabolic pathway
- 19 December 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 146 (6) , 1706-1710.e9
PPARγ promotes kaposiform hemangioendothelioma progression via the CD36-mediated lipid metabolic pathway
- Top Cited PapersOpen Access
- 21 August 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (10) , 1912-1927
TGF-β1 Promotes Angiogenesis via Endothelial-to-Mesenchymal Transition in Infantile Hemangioma
BACKGROUND: Infantile hemangioma (IH) is the most common benign tumor in infancy and severely affects aesthetics and function. Hemangioma-derived endothelial cells (HemECs) are the main cellular component of IH and contribute to angiogenesis in IH. TGF-β1 (transforming growth factor β1) can induce endothelial-to-mesenchymal transition (EndoMT). Few studies have investigated the role and mechanism of TGF-β1–mediated EndoMT in IH angiogenesis. METHODS: The expression of EndoMT markers in IH samples was evaluated via multiplexed immunofluorescence assay. Lentiviruses and small interfering RNA were used to regulate gene expression. Targeted lipidomic analysis was subsequently conducted. Protein interactions between TGF-β1 and potential effectors were examined. Biological changes in function were measured by migration, invasion, and tube formation in vitro and vessel formation in vivo. Autophagy-related structures were detected via transmission electron microscopy. BALB/C-nu mice were used for the hemangioma model. RESULTS: In this study, the active participation of EndoMT in proliferating IH was verified. TGF-β1 OE (TGF-β1 overexpression) induced EndoMT and promoted the migration, invasion, and angiogenic abilities of HemECs. In addition, TGF-β1 OE decreased the protein expression of CPT1A (carnitine palmitoyltransferase 1A). TGF-β1 treatment decreased the levels of L-palmitoylcarnitine (a downstream metabolite of CPT1A) in HemECs. Supplementation with L-palmitoylcarnitine partly reversed the functional changes caused by CPT1A KD (CPT1A knockdown). Furthermore, the effect of TGF-β1 OE +overexpression model of CPT1A was similar to that of CPT1A KD +L-palmitoylcarnitine in regulating the functional behaviors of HemECs. R(+) propranolol inhibited HemECs EndoMT and vessel formation in vivo. CONCLUSIONS: TGF-β1–mediated EndoMT promotes angiogenesis in IH. Targeting TGF-β1 could be a promising therapeutic strategy for inhibiting IH progression.
- 21 August 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 45 (10) , 1912-1927
Top Cited PapersOpen AccessTGF-β1 Promotes Angiogenesis via Endothelial-to-Mesenchymal Transition in Infantile Hemangioma
BACKGROUND: Infantile hemangioma (IH) is the most common benign tumor in infancy and severely affects aesthetics and function. Hemangioma-derived endothelial cells (HemECs) are the main cellular component of IH and contribute to angiogenesis in IH. TGF-β1 (transforming growth factor β1) can induce endothelial-to-mesenchymal transition (EndoMT). Few studies have investigated the role and mechanism of TGF-β1–mediated EndoMT in IH angiogenesis. METHODS: The expression of EndoMT markers in IH samples was evaluated via multiplexed immunofluorescence assay. Lentiviruses and small interfering RNA were used to regulate gene expression. Targeted lipidomic analysis was subsequently conducted. Protein interactions between TGF-β1 and potential effectors were examined. Biological changes in function were measured by migration, invasion, and tube formation in vitro and vessel formation in vivo. Autophagy-related structures were detected via transmission electron microscopy. BALB/C-nu mice were used for the hemangioma model. RESULTS: In this study, the active participation of EndoMT in proliferating IH was verified. TGF-β1 OE (TGF-β1 overexpression) induced EndoMT and promoted the migration, invasion, and angiogenic abilities of HemECs. In addition, TGF-β1 OE decreased the protein expression of CPT1A (carnitine palmitoyltransferase 1A). TGF-β1 treatment decreased the levels of L-palmitoylcarnitine (a downstream metabolite of CPT1A) in HemECs. Supplementation with L-palmitoylcarnitine partly reversed the functional changes caused by CPT1A KD (CPT1A knockdown). Furthermore, the effect of TGF-β1 OE +overexpression model of CPT1A was similar to that of CPT1A KD +L-palmitoylcarnitine in regulating the functional behaviors of HemECs. R(+) propranolol inhibited HemECs EndoMT and vessel formation in vivo. CONCLUSIONS: TGF-β1–mediated EndoMT promotes angiogenesis in IH. Targeting TGF-β1 could be a promising therapeutic strategy for inhibiting IH progression.
- 11 November 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115922
Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells
- 11 November 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115922
Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells
- Open Access
- 2 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Case Report: Pancreatic and hepatic kaposiform hemangioendothelioma presenting as consumptive coagulopathy and right hepatic atrophy
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that causes progressive angiogenesis and lymphangiogenesis, which often occurs in the skin or soft tissue, with an acute onset and rapid progression. A 4-year-old girl was admitted to our hospital with a 2-year history of thrombocytopenia, combined with right hepatic atrophy and pancreatic lesion for 3 months. At the age of two, she developed purpura and thrombocytopenia was detected, after treatment with gamma globulin and corticosteroids, the platelet count normalized, but it dropped immediately at lower doses. One year after the cessation of corticosteroids therapy, the patient presented with abdominal pain and abnormal liver function and the magnetic resonance imaging (MRI) revealed right hepatic atrophy and pancreatic occupancy, but the first liver biopsy did not reveal any positive pathological results. By analyzing the clinical manifestations in conjunction with MRI and abnormal coagulation, we considered that the patient might be diagnosed as KHE with Kasabach-Merritt phenomenon, however, sirolimus treatment was ineffective and pancreatic biopsy only showed a tendency for tumors of vascular origin. Finally, we performed a Whipple operation after the right hepatic artery embolization, histological and immunohistochemical examination suggested KHE. Three months postoperatively, the patient’s liver function, pancreatic enzymes and blood clotting function gradually returned to normal. KHEs may result in significant blood loss with worsening of the coagulopathy and functional impairment, timely surgical intervention for KHE is necessary when non-invasive or minimally invasive treatment is ineffective, or the symptoms of tumor compression are obvious.
- 2 May 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13
Open AccessCase Report: Pancreatic and hepatic kaposiform hemangioendothelioma presenting as consumptive coagulopathy and right hepatic atrophy
Kaposiform hemangioendothelioma (KHE) is a rare vascular tumor that causes progressive angiogenesis and lymphangiogenesis, which often occurs in the skin or soft tissue, with an acute onset and rapid progression. A 4-year-old girl was admitted to our hospital with a 2-year history of thrombocytopenia, combined with right hepatic atrophy and pancreatic lesion for 3 months. At the age of two, she developed purpura and thrombocytopenia was detected, after treatment with gamma globulin and corticosteroids, the platelet count normalized, but it dropped immediately at lower doses. One year after the cessation of corticosteroids therapy, the patient presented with abdominal pain and abnormal liver function and the magnetic resonance imaging (MRI) revealed right hepatic atrophy and pancreatic occupancy, but the first liver biopsy did not reveal any positive pathological results. By analyzing the clinical manifestations in conjunction with MRI and abnormal coagulation, we considered that the patient might be diagnosed as KHE with Kasabach-Merritt phenomenon, however, sirolimus treatment was ineffective and pancreatic biopsy only showed a tendency for tumors of vascular origin. Finally, we performed a Whipple operation after the right hepatic artery embolization, histological and immunohistochemical examination suggested KHE. Three months postoperatively, the patient’s liver function, pancreatic enzymes and blood clotting function gradually returned to normal. KHEs may result in significant blood loss with worsening of the coagulopathy and functional impairment, timely surgical intervention for KHE is necessary when non-invasive or minimally invasive treatment is ineffective, or the symptoms of tumor compression are obvious.
- Open Access
- 25 June 2022
- Published by Springer Nature in Dermatology and Therapy
- Vol. 12 (7) , 1659-1670
Maternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size
Introduction Infantile hemangioma (IH) is the most common benign tumor in infancy, but information about its pathogenesis is limited. The aim of this study was to determine maternal and perinatal risk factors for IH. Methods A total of 1033 IH patients were enrolled in the study between 2017 and 2020. IH patients were matched with controls by sex. Trained investigators collected detailed information from the participants. Logistic regression models were used for multivariate analysis. Results The statistical analysis demonstrated that miscarriage history (odds ratio [OR] = 4.275; 95% confidence interval [CI] [3.195, 5.720]), anemia in pregnancy (OR = 4.228; 95% CI [3.083, 5.799]), preterm premature rupture of membranes (PPROM) (OR = 3.182; 95% CI [1.359, 7.454]), placenta previa (OR = 2.440; 95% CI [1.787, 3.333]), threatened miscarriage (OR = 2.290; 95% CI [1.726, 3.039]), premature rupture of membranes (PROM) (OR = 1.785; P < 0.05), progesterone use (OR = 1.614; P < 0.001) and abnormal amniotic fluid volume (OR = 1.499; P < 0.05) were independent risk factors for IH. Gestational diabetes mellitus (GDM) (OR = 0.607; 95% CI [0.464, 0.794]), multiple gestations (OR = 0.407; 95% CI [0.232, 0.713]), hypothyroidism (OR = 0.407; 95% CI [0.227, 0.730]) and uterine fibroids (OR = 0.393; 95% CI [0.250, 0.618]) may reduce the risk of IH. Conclusions Maternal and perinatal factors are closely associated with IH occurrence. Our study provides reliable clues to guide further exploration of the pathogenesis of IH. Trial Registration ClinicalTrials.gov, NCT03331744. Plain Language Summary Infantile hemangioma is the most common benign tumor in children, which seriously affects appearance and function and even threatens life. The pathogenesis is not clear, a detailed case-control study of the maternal and perinatal periods with a large sample size will facilitate the development of individualized and precise treatment, early and timely interventions for high-risk children and improvement of prognosis. Our study found that miscarriage history, anemia in pregnancy, preterm premature rupture of membranes (PPROM), placenta previa, threatened miscarriage, premature rupture of membranes (PROM), progesterone use and abnormal amniotic fluid volume were independent risk factors for IH.
- 25 June 2022
- Published by Springer Nature in Dermatology and Therapy
- Vol. 12 (7) , 1659-1670
Open AccessMaternal and Perinatal Risk Factors for Infantile Hemangioma: A Matched Case-Control Study with a Large Sample Size
Introduction Infantile hemangioma (IH) is the most common benign tumor in infancy, but information about its pathogenesis is limited. The aim of this study was to determine maternal and perinatal risk factors for IH. Methods A total of 1033 IH patients were enrolled in the study between 2017 and 2020. IH patients were matched with controls by sex. Trained investigators collected detailed information from the participants. Logistic regression models were used for multivariate analysis. Results The statistical analysis demonstrated that miscarriage history (odds ratio [OR] = 4.275; 95% confidence interval [CI] [3.195, 5.720]), anemia in pregnancy (OR = 4.228; 95% CI [3.083, 5.799]), preterm premature rupture of membranes (PPROM) (OR = 3.182; 95% CI [1.359, 7.454]), placenta previa (OR = 2.440; 95% CI [1.787, 3.333]), threatened miscarriage (OR = 2.290; 95% CI [1.726, 3.039]), premature rupture of membranes (PROM) (OR = 1.785; P < 0.05), progesterone use (OR = 1.614; P < 0.001) and abnormal amniotic fluid volume (OR = 1.499; P < 0.05) were independent risk factors for IH. Gestational diabetes mellitus (GDM) (OR = 0.607; 95% CI [0.464, 0.794]), multiple gestations (OR = 0.407; 95% CI [0.232, 0.713]), hypothyroidism (OR = 0.407; 95% CI [0.227, 0.730]) and uterine fibroids (OR = 0.393; 95% CI [0.250, 0.618]) may reduce the risk of IH. Conclusions Maternal and perinatal factors are closely associated with IH occurrence. Our study provides reliable clues to guide further exploration of the pathogenesis of IH. Trial Registration ClinicalTrials.gov, NCT03331744. Plain Language Summary Infantile hemangioma is the most common benign tumor in children, which seriously affects appearance and function and even threatens life. The pathogenesis is not clear, a detailed case-control study of the maternal and perinatal periods with a large sample size will facilitate the development of individualized and precise treatment, early and timely interventions for high-risk children and improvement of prognosis. Our study found that miscarriage history, anemia in pregnancy, preterm premature rupture of membranes (PPROM), placenta previa, threatened miscarriage, premature rupture of membranes (PROM), progesterone use and abnormal amniotic fluid volume were independent risk factors for IH.
- 1 July 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2160-052X, 51-58
Sparstition: A Partitioning Scheme for Large-Scale Sparse Matrix Vector Multiplication on FPGA
Sparse Matrix Vector Multiplication (SpMV) is a key kernel in various domains, that is known to be difficult to parallelize efficiently due to the low spatial locality of data. This is problematic for computing large-scale SpMV due to limited cache sizes but also in achieving speedups through parallel execution. To address these issues, we present 1) sparstition, a novel partitioning scheme that enables computing SpMV without the need to do any major post-processing steps, and 2) a corresponding HLS-based hardware design that is able to perform large-scale SpMV efficiently. The design is pipelined so the matrix size is limited only by the size of the off-chip memory (DRAM) and not by the available on-chip memory (BRAMs). Our experimental results, performed on a ZedBoard, show that we achieve a computational throughput of up to 300 MFLOPS in single-precision and 108 MFLOPS in double-precision, an improvement of 2.6X on average compared to current state-of-the-art HLS results. Finally, we predict that sparstition can boost the computational throughput of HLS-based SpMV kernel to over 10 GFLOPS when using High Bandwidth Memories.
- 1 July 2019
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 2160-052X, 51-58
Sparstition: A Partitioning Scheme for Large-Scale Sparse Matrix Vector Multiplication on FPGA
Sparse Matrix Vector Multiplication (SpMV) is a key kernel in various domains, that is known to be difficult to parallelize efficiently due to the low spatial locality of data. This is problematic for computing large-scale SpMV due to limited cache sizes but also in achieving speedups through parallel execution. To address these issues, we present 1) sparstition, a novel partitioning scheme that enables computing SpMV without the need to do any major post-processing steps, and 2) a corresponding HLS-based hardware design that is able to perform large-scale SpMV efficiently. The design is pipelined so the matrix size is limited only by the size of the off-chip memory (DRAM) and not by the available on-chip memory (BRAMs). Our experimental results, performed on a ZedBoard, show that we achieve a computational throughput of up to 300 MFLOPS in single-precision and 108 MFLOPS in double-precision, an improvement of 2.6X on average compared to current state-of-the-art HLS results. Finally, we predict that sparstition can boost the computational throughput of HLS-based SpMV kernel to over 10 GFLOPS when using High Bandwidth Memories.